High BAX/BCL2 mRNA ratio predicts favorable prognosis in laryngeal squamous cell carcinoma, particularly in patients with negative lymph nodes at the time of diagnosis.

[1]  A. Scorilas,et al.  Apoptosis-related BCL2-family members: Key players in chemotherapy. , 2014, Anti-cancer agents in medicinal chemistry.

[2]  A. Scorilas,et al.  Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma , 2014, Tumor Biology.

[3]  T. Kamimoto,et al.  MicroRNA-196a Is a Putative Diagnostic Biomarker and Therapeutic Target for Laryngeal Cancer , 2013, PloS one.

[4]  A. Scorilas,et al.  Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study , 2013, BMC Cancer.

[5]  Wei Zhang,et al.  Overexpression of miR -155 Promotes Proliferation and Invasion of Human Laryngeal Squamous Cell Carcinoma via Targeting SOCS1 and STAT3 , 2013, PloS one.

[6]  A. Scorilas,et al.  Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. , 2013, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[7]  G. Marioni.  Letter to the editors: Essentials for an updated epidemiology of laryngeal carcinoma. , 2012, Cancer treatment reviews.

[8]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[9]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[10]  A. Scorilas,et al.  Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor , 2010, Tumor Biology.

[11]  A. Petrie,et al.  Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients , 2010, Head & neck oncology.

[12]  T. Carey,et al.  Genotyping of 73 UM‐SCC head and neck squamous cell carcinoma cell lines , 2009, Head & neck.

[13]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[14]  C. Sotiriou,et al.  Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation , 2006, Head & neck.

[15]  Andreas Scorilas,et al.  BCL2 Family of Apoptosis-Related Genes: Functions and Clinical Implications in Cancer , 2006, Critical reviews in clinical laboratory sciences.

[16]  J. Greenman,et al.  Bcl-2 expression predicts radiotherapy failure in laryngeal cancer , 2005, British Journal of Cancer.

[17]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[18]  Takashi Suzuki,et al.  Protein expression of p53 and Bcl-2 has a strong correlation with radiation resistance of laryngeal squamous cell carcinoma but does not predict the radiation failure before treatment. , 2003, Oncology reports.

[19]  J. Verdebout,et al.  Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis , 2003, British Journal of Cancer.

[20]  S. Ell,et al.  Overexpression of Bcl‐2 in squamous cell carcinoma of the larynx: A marker of radioresistance , 2002, International journal of cancer.

[21]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[22]  G. Wu,et al.  Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[23]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[24]  S. H. Cheng,et al.  Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Asai,et al.  Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax , 1999, Oncogene.

[26]  O. Bairey,et al.  Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[28]  G. Pruneri,et al.  Clinical relevance of p53 and bcl‐2 protein over‐expression in laryngeal squamous‐cell carcinoma , 1998, International journal of cancer.

[29]  J. Cooper,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Gado,et al.  Comparison of Clinical Evaluation and Computed Tomographic Diagnostic Accuracy for Tumors of the Larynx and Hypopharynx , 1996, The Laryngoscope.

[31]  John Calvin Reed,et al.  Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2 (*) , 1996, The Journal of Biological Chemistry.

[32]  S. Restivo,et al.  Prognostic significance of cell kinetics in laryngeal squamous cell carcinoma: clinicopathological associations. , 1995, Cancer research.

[33]  E. Campo,et al.  p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors , 1995, The Journal of pathology.

[34]  Z. Oltvai,et al.  BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax , 1994, Nature.

[35]  Z. Oltvai,et al.  Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. , 1993, Seminars in cancer biology.

[36]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[37]  J C Reed,et al.  Differential effects of Bcl-2 on T and B cells in transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[39]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[40]  A. Scorilas,et al.  Molecular Biomarkers of Laryngeal Cancer Laryngeal squamous cell carcinoma (LSCC) Tumor markers , 2015 .

[41]  Ming Liu,et al.  Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. , 2013, The American journal of pathology.

[42]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[43]  G. Pruneri,et al.  Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  G. Neri,et al.  Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.